Cancer Therapy

You have full text access to this OnlineOpen article

Dietary lariciresinol attenuates mammary tumor growth and reduces blood vessel density in human MCF-7 breast cancer xenografts and carcinogen-induced mammary tumors in rats

  1. Niina M. Saarinen1,†,*,
  2. Anni Wärri1,
  3. Ruud P.M. Dings2,
  4. Maarit Airio1,
  5. Annika I. Smeds3,
  6. Sari Mäkelä1,4

Article first published online: 4 JUN 2008

DOI: 10.1002/ijc.23614

Issue

International Journal of Cancer

International Journal of Cancer

Volume 123, Issue 5, pages 1196–1204, 1 September 2008

Additional Information

How to Cite

Saarinen, N. M., Wärri, A., Dings, R. P.M., Airio, M., Smeds, A. I. and Mäkelä, S. (2008), Dietary lariciresinol attenuates mammary tumor growth and reduces blood vessel density in human MCF-7 breast cancer xenografts and carcinogen-induced mammary tumors in rats. Int. J. Cancer, 123: 1196–1204. doi: 10.1002/ijc.23614

Author Information

  1. 1

    Functional Foods Forum, University of Turku, Turku, Finland

  2. 2

    Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN

  3. 3

    Department of Biochemistry and Pharmacy, Åbo Akademi University, BioCity, Turku, Finland

  4. 4

    Department of Biochemistry and Food Chemistry, University of Turku, Turku, Finland

  1. †

    Fax: +358-2-333-6862.

*Functional Foods Forum, University of Turku, FI-20014, Turku, Finland

Publication History

  1. Issue published online: 17 JUN 2008
  2. Article first published online: 4 JUN 2008
  3. Manuscript Accepted: 6 MAR 2008
  4. Manuscript Received: 16 NOV 2007

Funded by

  • TEKES, National Technology Agency of Finland. Grant Numbers: 40078/01, 40056/03
  • Academy of Finland. Grant Number: 115459/06

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (348K)

References

  • 1
    Michels KB,Mohllajee AP,Roset-Bahmanyar E,Beehler GP,Moysich KB. Diet and breast cancer: a review of the prospective observational studies. Cancer 2007; 109: 2712–49.
    Direct Link:
  • 2
    Scalbert A,Williamson G. Dietary intake and bioavailability of polyphenols. J Nutr 2000; 130: 2073S–S85.
  • 3
    Saarinen NM,Bingham C,Lorenzetti S,Mortensen A,Mäkelä S,Penttinen P,Sørensen IK,Valsta LM,Virgili F,Vollmer G,Wärri A,Zierau O. Tools to evaluate estrogenic potency of dietary phytoestrogens: a consensus paper from the EU thematic network “PHYTOHEALTH” (QLKI-2002–2453). Genes Nutr 2006; 1: 143–58.
  • 4
    Smeds AI,Eklund PC,Sjöholm RE,Willför SM,Nishibe S,Deyama T,Holmbom BR. Quantification of a broad spectrum of lignans in cereals, oilseeds, and nuts. J Agric Food Chem 2007; 55: 1337–46.
  • 5
    Thompson LU,Boucher BA,Liu Z,Cotterchio M,Kreiger N. Phytoestrogen content of foods consumed in Canada, including isoflavones, lignans, and coumestan. Nutr Cancer 2006; 54: 184–201.
  • 6
    Milder IE,Arts IC,van de Putte B,Venema DP,Hollman PC. Lignan contents of Dutch plant foods: a database including lariciresinol, pinoresinol, secoisolariciresinol and matairesinol. Br J Nutr 2005; 93: 393–402.
  • 7
    Peñalvo JL,Haajanen KM,Botting N,Adlercreutz H. Quantification of lignans in food using isotope dilution gas chromatography/mass spectrometry. J Agric Food Chem 2005; 53: 9342–47.
  • 8
    Mazur W,Adlercreutz H. Natural and anthropogenic environmental oestrogens: the scientific basis for risk assessment. Naturally occurring oestrogens in food. Pure Appl Chem 1998; 70: 1759–76.
  • 9
    Axelson M,Setchell KD. The excretion of lignans in rats—evidence for an intestinal bacterial source for this new group of compounds. FEBS Lett 1981; 123: 337–42.
  • 10
    Heinonen S,Nurmi T,Liukkonen K,Poutanen K,Wähälä K,Deyama T,Nishibe S,Adlercreutz H. In vitro metabolism of plant lignans: new precursors of mammalian lignans enterolactone and enterodiol. J Agric Food Chem 2001; 49: 3178–86.
  • 11
    Piller R,Chang-Claude J,Linseisen J. Plasma enterolactone and genistein and the risk of premenopausal breast cancer. Eur J Cancer Prev 2006; 15: 225–32.
  • 12
    Thanos J,Cotterchio M,Boucher BA,Kreiger N,Thompson LU. Adolescent dietary phytoestrogen intake and breast cancer risk (Canada). Cancer Causes Control 2006; 17: 1253–61.
  • 13
    Piller R,Verla-Tebit E,Wang-Gohrke S,Linseisen J,Chang-Claude J. CYP17 genotype modifies the association between lignan supply and premenopausal breast cancer risk in humans. J Nutr 2006; 136: 1596–1603.
  • 14
    McCann SE,Muti P,Vito D,Edge SB,Trevisan M,Freudenheim JL. Dietary lignan intakes and risk of pre- and postmenopausal breast cancer. Int J Cancer 2004; 111: 440–3.
    Direct Link:
  • 15
    Hultén K,Winkvist A,Lenner P,Johansson R,Adlercreutz H,Hallmans G. An incident case-referent study on plasma enterolactone and breast cancer risk. Eur J Nutr 2002; 41: 168–76.
  • 16
    Zeleniuch-Jacquotte A,Adlercreutz H,Shore RE,Koenig KL,Kato I,Arslan AA,Toniolo P. Circulating enterolactone and risk of breast cancer: a prospective study in New York. Br J Cancer 2004; 91: 99–105.
  • 17
    Milder IE,Feskens EJ,Arts IC,Bueno de Mesquita HB,Hollman PC,Kromhout D. Intake of the plant lignans secoisolariciresinol, matairesinol, lariciresinol, and pinoresinol in Dutch men and women. J Nutr. 2005; 135: 1202–7.
  • 18
    Smeds AI,Hakala K,Hurmerinta TT,Kortela L,Saarinen NM,Mäkelä SI. Determination of plant and enterolignans in human serum by high-performance liquid chromatography with tandem mass spectrometric detection. J Pharm Biomed Anal 2006; 41: 898–905.
  • 19
    Bannwart C,Adlercreutz H,Wähälä K,Brunow G,Hase T. Detection and identification of the plant lignans lariciresinol, isolariciresinol and secoisolariciresinol in human urine. Clin Chim Acta 1989; 180: 293–301.
  • 20
    Nurmi T,Voutilainen S,Nyyssönen K,Adlercreutz H,Salonen JT. Liquid chromatography method for plant and mammalian lignans in human urine. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 798: 101–10.
  • 21
    Saarinen NM,Smeds A,Mäkelä SI,Ämmälä J,Hakala K,Pihlava JM,Ryhänen EL,Sjöholm R,Santti R. Structural determinants of plant lignans for the formation of enterolactone in vivo. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 777: 311–19.
  • 22
    Smeds AI,Saarinen NM,Hurmerinta TT,Penttinen PE,Sjöholm RE,Mäkelä SI. Urinary excretion of lignans after administration of isolated plant lignans to rats: the effect of single dose and ten-day exposures. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 813: 303–12.
  • 23
    Thompson LU,Seidl MM,Rickard SE,Orcheson LJ,Fong HH. Antitumorigenic effect of a mammalian lignan precursor from flaxseed. Nutr Cancer 1996; 26: 159–65.
  • 24
    Thompson LU,Rickard SE,Orcheson LJ,Seidl MM. Flaxseed and its lignan and oil components reduce mammary tumor growth at a late stage of carcinogenesis. Carcinogenesis 1996; 17: 1373–6.
  • 25
    Saarinen NM,Huovinen R,Wärri A,Mäkelä SI,Valentin-Blasini L,Sjöholm R,Ämmälä J,Lehtilä R,Eckerman C,Collan YU,Santti RS. Enterolactone inhibits the growth of 7,12-dimethylbenz(a)anthracene-induced mammary carcinomas in the rat. Mol Cancer Ther 2002; 1: 869–76.
  • 26
    Power KA,Saarinen NM,Chen JM,Thompson LU. Mammalian lignans enterolactone and enterodiol, alone and in combination with the isoflavone genistein, do not promote the growth of MCF-7 xenografts in ovariectomized athymic nude mice. Int J Cancer 2006; 118: 1316–20.
    Direct Link:
  • 27
    Bergman Jungeström M,Thompson LU,Dabrosin C. Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis, and secretion of vascular endothelial growth factor in human breast cancer xenografts in vivo. Clin Cancer Res 2007; 13: 1061–67.
  • 28
    Touillaud MS,Thiébaut AC,Fournier A,Niravong M,Boutron-Ruault MC,Clavel-Chapelon F. Dietary lignan intake and postmenopausal breast cancer risk by estrogen and progesterone receptor status. J Natl Cancer Inst 2007; 99: 475–86.
  • 29
    Anderegg RJ,Rowe JW. Lignans, the major component of resin from Araucaria angustifolia knots. Holzforschung 1974; 28: 171–5.
  • 30
    Garvin S,Dabrosin C. Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo. Cancer Res 2003; 63: 8742–8.
  • 31
    Chen J,Hui E,Ip T,Thompson LU. Dietary flaxseed enhances the inhibitory effect of tamoxifen on the growth of estrogen-dependent human breast cancer (mcf-7) in nude mice. Clin Cancer Res 2004; 10: 7703–11.
  • 32
    Archer FL,Orlando RA. Morphology, natural history and enzyme patterns in mammary tumors of the rat induced by 7,12-dimethylbenz(a)anthracene. Cancer Res 1968; 28: 217–24.
  • 33
    Dings RP,Loren M,Heun H,McNiel E,Griffioen AW,Mayo KH,Griffin RJ. Scheduling of radiation with angiogenesis inhibitors anginex and avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 2007; 13: 3395–402.
  • 34
    Wild R,Ramakrishnan S,Sedgewick J,Griffioen AW. Quantitative assessment of angiogenesis and tumor vessel architecture by compute-assisted digital image analysis: effects of VEGF-toxin conjugate on tumor microvessel density. Microvasc Res 2000; 59: 368–76.
  • 35
    Dings RP,Chen X,Hellebrekers DM,van Eijk LI,Zhang Y,Hoye TR,Griffioen AW,Mayo KH. Design of nonpeptidic topomimetics of antiangiogenic proteins with antitumor activities. J Natl Cancer Inst 2006; 98: 932–6.
  • 36
    Saarinen NM,Wärri A,Mäkelä SI,Eckerman C,Reunanen M,Ahotupa M,Salmi SM,Franke AA,Kangas L,Santti R. Hydroxymatairesinol, a novel enterolactone precursor with antitumor properties from coniferous tree (Picea abies). Nutr Cancer 2000; 36: 207–16.
  • 37
    Saarinen NM,Power KA,Chen J,Thompson LU. Lignans are accessible to human breast cancer xenografts in athymic mice. Nutr Cancer 2008; 60: 245–50.
  • 38
    Juntunen KS,Mazur WM,Liukkonen KH,Uehara M,Poutanen KS,Adlercreutz HC,Mykkänen HM. Consumption of wholemeal rye bread increases serum concentrations and urinary excretion of enterolactone compared with consumption of white wheat bread in healthy Finnish men and women. Br J Nutr. 2000; 84: 839–46.
  • 39
    Morton MS,Wilcox G,Wahlqvist ML,Griffiths K. Determination of lignan and isoflavonoids in human female plasma following dietary supplementation. J Endocrinol 1994; 142: 251–594.
  • 40
    Chen J,Power KA,Mann J,Cheng A,Thompson LU. Flaxseed alone or in combination with tamoxifen inhibits MCF-7 breast tumor growth in ovariectomized athymic mice with high circulating levels of estrogen. Exp Biol Med (Maywood) 2007; 232: 1071–80.
  • 41
    Welshons WV,Murphy CS,Koch R,Calaf G,Jordan VC. Stimulation of breast cancer cells in vitro by the environmental estrogen enterolactone and the phytoestrogen equol. Breast Cancer Res Treat 1987; 10: 169–75.
  • 42
    Mousavi Y,Adlercreutz H. Enterolactone and estradiol inhibit each other's proliferative effect on MCF-7 breast cancer cells in culture. JSteroid Biochem Mol Biol 1992; 41: 615–19.
  • 43
    Sathyamoorthy N,Wang TT,Phang JM. Stimulation of pS2 expression by diet-derived compounds. Cancer Res 1994; 54: 957–61.
  • 44
    Wang C,Kurzer MS. Phytoestrogen concentration determines effects on DNA synthesis in human breast cancer cells. Nutr Cancer 1997; 8: 236–47.
  • 45
    Wang C,Kurzer MS. Effects of phytoestrogens on DNA synthesis in MCF-7 cells in the presence of estradiol or growth factors. Nutr Cancer 1998; 31: 90–100.
  • 46
    Saarinen NM,Wärri A,Airio M,Smeds A,Mäkelä S. Role of dietary lignans in the reduction of breast cancer risk. Mol Nutr Food Res 2007; 51: 857–66.
    Direct Link:
  • 47
    Airio M,Wärri A,Mäkelä S,Saarinen NM. In vitro proliferation assays do not fully predict the MCF-7 tumor growth response to lignan lariciresinol in vivo. Proc Am Assoc Cancer Res 2005; 11: 1223–4.
  • 48
    Chen J,Saggar J,Webster M,Thompson LU. Component of flaxseed responsible for its ability to regress the growth of established human breast tumors (MCF-7) in ovariectomized nude mice. Proc Am Assoc Cancer Res 2007; 48: 1028.
  • 49
    Mueller SO,Simon S,Chae K,Metzler M,Korach KS. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor α (ERα) and ERβ in human cells. Toxicol Sci 2004; 80: 14–25.
  • 50
    Penttinen P,Jaehrling J,Damdimopoulos AE,Inzunza J,Lemmen JG,van der Saag P,Pettersson K,Gauglitz G,Mäkelä S,Pongratz I. Diet-derived polyphenol metabolite enterolactone is a tissue-specific estrogen receptor activator. Endocrinology 2007; 148: 4875–86.
  • 51
    Kim HJ,Cui X,Hilsenbeck SG,Lee AV. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer. Clin Cancer Res 2006; 12: S1013–S18.
  • 52
    Skliris GP,Munot K,Bell SM,Carder PJ,Lane S,Horgan K,Lansdown MR,Parkes AT,Hanby AM,Markham AF,Speirs V. Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol 2003; 201: 213–20.
    Direct Link:
  • 53
    Mann S,Laucirica R,Carlson N,Younes PS,Ali N,Younes A,Li Y,Younes M. Estrogen receptor beta expression in invasive breast cancer. Hum Pathol 2001; 32: 113–18.
  • 54
    Fuqua SA,Schiff R,Parra I,Moore JT,Mohsin SK,Osborne CK,Clark GM,Allred DC. Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res 2003; 63: 2434–9.
  • 55
    Kurebayashi J,Otsuki T,Kunisue H,Tanaka K,Yamamoto S,Sonoo H. Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer. Clin Cancer Res 2000; 6: 512–18.
  • 56
    Kenny PA,Lee GY,Myers CA,Neve RM,Semeiks JR,Spellman PT,Lorenz K,Lee EH,Barcellos-Hoff MH,Petersen OW,Gray JW,Bissel MJ. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 2007; 1: 84–96.
  • 57
    Harvell DM,Richer JK,Allred DC,Sartorius CA,Horwitz KB. Estradiol regulates different genes in human breast tumor xenografts compared with the identical cells in culture. Endocrinology 2006; 147: 700–13.
  • 58
    Vargo-Gogola T,Rosen JM. Modelling breast cancer: one size does not fit all. Nat Rev Cancer 2007; 7: 659–72.
  • 59
    Behrens D,Gill JH,Fichtner I. Loss of tumourigenicity of stably ERbeta-transfected MCF-7 breast cancer cells. Mol Cell Endocrinol 2007; 274: 19–29.
  • 60
    Paruthiyil S,Parmar H,Kerekatte V,Cunha GR,Firestone GL,Leitman DC. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 2004; 64: 423–8.
  • 61
    Miura D,Saarinen NM,Miura Y,Santti R,Yagasaki K. Hydroxymatairesinol and its mammalian metabolite enterolactone reduce the growth and metastasis of subcutaneous AH109A hepatomas in rats. Nutr Cancer 2007; 58: 49–59.
  • 62
    Danbara N,Yuri T,Tsujita-Kyutoku M,Tsukamoto R,Uehara N,Tsubura A. Enterolactone induces apoptosis and inhibits growth of Colo 201 human colon cancer cells both in vitro and in vivo. Anticancer Res 2005; 25: 2269–76.
  • 63
    Ferrara N,Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4–25.
View Full Article (HTML) Get PDF (348K)